Catheter Precision (VTAK) AI Stock Analysis

• Market Cap: $3.38M
• Dividend Yield: N/A
• Average Volume (3M): 309.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: 82.96%
• EPS Growth: 82.04%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 1,668,375
• 10 Day Avg. Volume: 759,143
• 30 Day Avg. Volume: 309,336
• PEG Ratio: 0.03
• Price to Book (P/B): 2.38
• Price to Sales (P/S): 66.59
• P/FCF Ratio: -3.00
• Enterprise Value/Market Cap: 10.56
• Enterprise Value/Revenue: 48.88
• Enterprise Value/Gross Profit: 241.11
• Enterprise Value/Ebitda: -2.63
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.50 ▼(-17.13% Downside)

The score is primarily driven by weak financial performance—declining revenue, ongoing losses, and negative free cash flow. Technicals further weigh on the rating with a clear downtrend and negative momentum, despite oversold readings. Valuation provides limited offset because negative earnings make P/E less informative and there is no dividend support.

Positive Factors

Global Expansion

The successful implementation of LockeT in Dublin marks a significant step in Catheter Precision's global expansion, enhancing its market presence and potentially driving long-term revenue growth in international markets.

Product Innovation

The launch of LockeT in new markets like Switzerland and South Africa demonstrates Catheter Precision's commitment to innovation and expanding its product offerings, which can strengthen its competitive position in the medical devices industry.

Strategic Partnerships

Securing a tender from a leading hospital in Hungary highlights Catheter Precision's ability to form strategic partnerships, which can enhance its market reach and support sustained revenue growth through increased adoption of its products.

Negative Factors

Declining Revenue

The persistent decline in revenue from 2019 to 2024 indicates challenges in market demand or competitive pressures, which could impact long-term financial stability and growth prospects.

Negative Cash Flow

Negative free cash flow suggests that Catheter Precision is spending more cash than it generates, which can strain financial resources and limit the company's ability to invest in growth opportunities or weather economic downturns.

Operating Losses

Ongoing operating and net losses indicate inefficiencies or high costs relative to revenue, which can undermine profitability and hinder the company's ability to reinvest in its business for future growth.

Catheter Precision Business Overview & Revenue Model

Company Description

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.

How the Company Makes Money

Catheter Precision generates revenue primarily through the sale of its cardiac mapping systems and related software solutions to hospitals and healthcare providers. The company also earns income from ongoing sales of consumable products associated with its systems, including catheters and accessories used during procedures. Additionally, Catheter Precision may benefit from service contracts and maintenance agreements for their equipment, providing a recurring revenue stream. Strategic partnerships with hospitals and medical institutions, as well as collaborations with research organizations, may further enhance their market reach and contribute to their overall earnings.

Catheter Precision Financial Statement Overview

Summary

The financial performance is weak, with significant declines in revenue and persistent operational losses. The balance sheet shows moderate leverage but negative return on equity, and cash flow analysis indicates ongoing negative free cash flow, highlighting cash flow challenges.

Income Statement

The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.

Balance Sheet

The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.

Cash Flow

Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	730.00K	420.00K	442.00K	14.00K	22.00K	259.00K
Gross Profit	148.00K	378.00K	412.00K	-147.00K	-1.54M	-1.91M
EBITDA	-13.56M	-11.30M	-15.11M	-22.37M	-25.85M	-33.04M
Net Income	-17.38M	-16.64M	-70.57M	-26.86M	-25.07M	-36.05M
Balance Sheet
Total Assets	25.47M	27.77M	30.74M	16.84M	21.04M	33.44M
Cash, Cash Equivalents and Short-Term Investments	1.07M	2.87M	3.56M	15.86M	15.04M	23.91M
Total Debt	3.48M	1.79M	372.00K	0.00	2.26M	4.88M
Total Liabilities	19.02M	16.01M	9.54M	7.58M	7.37M	12.29M
Stockholders Equity	6.78M	11.76M	21.19M	9.26M	13.67M	21.15M
Cash Flow
Free Cash Flow	-9.66M	-9.34M	-20.70M	-22.59M	-27.89M	-28.37M
Operating Cash Flow	-9.64M	-9.27M	-20.62M	-22.57M	-27.63M	-28.30M
Investing Cash Flow	-51.00K	-67.00K	-61.00K	21.00K	3.80M	15.93M
Financing Cash Flow	9.50M	8.65M	8.39M	23.36M	14.96M	21.69M

Catheter Precision Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Neutral. The current price of 1.81 is below the 20-day moving average (MA) of 2.06, below the 50-day MA of 2.14, and below the 200-day MA of 3.69, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 48.89 is Neutral, neither overbought nor oversold. The STOCH value of 84.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VTAK.

Catheter Precision Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HSCS	46 Neutral	$10.65M	-0.49	-220.42%	―	-41.03%	35.71%
AEMD	45 Neutral	$2.39M	-0.05	-191.39%	―	―	76.53%
PAVM	45 Neutral	$7.21M	-0.42	20.03%	―	-99.28%	-46.16%
NUWE	43 Neutral	$3.27M	-0.02	-467.14%	―	-8.93%	97.80%
VTAK	42 Neutral	$3.38M	-0.05	-173.74%	―	82.96%	82.04%
VERO	40 Underperform	$2.84M	-0.03	-854.61%	―	-12.39%	44.61%

Catheter Precision Corporate Events

Catheter Precision Ends At-Market-Offering Agreement

On November 17, 2025, Catheter Precision, Inc. announced the termination of its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., effective November 24, 2025. The agreement allowed the company to sell shares of its common stock up to $4.3 million, of which approximately $4.0 million had been sold prior to termination. The company will not incur any penalties due to this termination.

The most recent analyst rating on (VTAK) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.

Catheter Precision Increases Authorized Shares to 500 Million

On October 10, 2025, Catheter Precision held a Special Meeting of stockholders where approximately 43.1% of the outstanding shares of common stock were represented. During the meeting, stockholders approved three proposals: an increase in authorized shares from 60 million to 500 million, the ratification of WithumSmith+Brown, PC as the independent accounting firm for 2026, and the potential adjournment or postponement of the meeting to solicit more votes if necessary.

The most recent analyst rating on (VTAK) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.